Kelly E Dunn1, Van L King1, Robert K Brooner2. 1. Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, United States. 2. Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, United States. Electronic address: rkbrooner@jhmi.edu.
Abstract
BACKGROUND: Adherence with psychiatric medication is a critical issue that has serious individual and public health implications. This is a secondary analysis of a large-scale clinical treatment trial of co-occurring substance use and psychiatric disorder. METHOD:Participants (n=153) who received a clinically-indicated psychiatric medication ≥30 days during the 12-month study and provided corresponding data fromMedication Event Monitoring System (MEMS) and Morisky Medication Taking Adherence Scale (MMAS) self-report adherence ratings were included in the analyses. Accuracy in MEMS caps openings was customized to each participant's unique required dosing schedule. RESULTS: Consistent with expectations, MEMS-based adherence declined slowly over time, though MMAS scores of forgetting medication remained high and did not change over the 12-month study. MEMS caps openings were not significantly impacted by any baseline or treatment level variables, whereas MMAS scores were significantly associated with younger age and presence of an Axis I disorder and antisocial personality disorder, or any cluster B diagnoses. CONCLUSIONS: Results suggest that MEMS caps may be a more objective method for monitoring adherence in patients with co-occurring substance use and psychiatric disorder relative to the MMAS self-report. Participants in this study were able to successfully use the MEMS caps for a 12-month period with <1% lost or broken caps, suggesting this comorbid population is able to use the MEMS successfully. Ultimately, these data suggest that an objective method for monitoring adherence in this treatment population yield more accurate outcomes relative to self-report.
RCT Entities:
BACKGROUND: Adherence with psychiatric medication is a critical issue that has serious individual and public health implications. This is a secondary analysis of a large-scale clinical treatment trial of co-occurring substance use and psychiatric disorder. METHOD:Participants (n=153) who received a clinically-indicated psychiatric medication ≥30 days during the 12-month study and provided corresponding data from Medication Event Monitoring System (MEMS) and Morisky Medication Taking Adherence Scale (MMAS) self-report adherence ratings were included in the analyses. Accuracy in MEMS caps openings was customized to each participant's unique required dosing schedule. RESULTS: Consistent with expectations, MEMS-based adherence declined slowly over time, though MMAS scores of forgetting medication remained high and did not change over the 12-month study. MEMS caps openings were not significantly impacted by any baseline or treatment level variables, whereas MMAS scores were significantly associated with younger age and presence of an Axis I disorder and antisocial personality disorder, or any cluster B diagnoses. CONCLUSIONS: Results suggest that MEMS caps may be a more objective method for monitoring adherence in patients with co-occurring substance use and psychiatric disorder relative to the MMAS self-report. Participants in this study were able to successfully use the MEMS caps for a 12-month period with <1% lost or broken caps, suggesting this comorbid population is able to use the MEMS successfully. Ultimately, these data suggest that an objective method for monitoring adherence in this treatment population yield more accurate outcomes relative to self-report.
Authors: Judith Bosman; Peter G J Ter Horst; Jan Pieter Smit; Jeroen R Dijkstra; Hans R Beekhuis; Robbert J Slingersland; Wobbe Hospes Journal: Ther Adv Psychopharmacol Date: 2014-04
Authors: Bernard Vrijens; Eric Tousset; Richard Rode; Richard Bertz; Steve Mayer; John Urquhart Journal: J Clin Pharmacol Date: 2005-04 Impact factor: 3.126
Authors: Martha Sajatovic; Dawn I Velligan; Peter J Weiden; Marcia A Valenstein; Gbenga Ogedegbe Journal: J Psychosom Res Date: 2009-07-25 Impact factor: 3.006
Authors: Sarah Clifford; Magaly Perez-Nieves; Anne M Skalicky; Matthew Reaney; Karin S Coyne Journal: Curr Med Res Opin Date: 2014-02-11 Impact factor: 2.580
Authors: Wilson M Compton; Linda B Cottler; Jacqueline L Jacobs; Arbi Ben-Abdallah; Edward L Spitznagel Journal: Am J Psychiatry Date: 2003-05 Impact factor: 18.112
Authors: Pieter J Carpentier; Paul F M Krabbe; Mijke T van Gogh; Lieke J M Knapen; Jan K Buitelaar; Cor A J de Jong Journal: Am J Addict Date: 2009 Nov-Dec
Authors: Jackson M Steinkamp; Nathaniel Goldblatt; Jacob T Borodovsky; Amy LaVertu; Ian M Kronish; Lisa A Marsch; Zev Schuman-Olivier Journal: JMIR Ment Health Date: 2019-03-12